000			02037 a2200553 4500
005			20250517213852.0
264		0	_c20190327
008			201903s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-018-0599-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aLui, Arthur
245	0	0	_aA multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. _h[electronic resource]
260			_bInvestigational new drugs _c08 2018
300			_a674-682 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCapecitabine _xadministration & dosage
650	0	4	_aDrug Administration Schedule
650	0	4	_aEsophageal Neoplasms _xdrug therapy
650	0	4	_aEsophagogastric Junction _xdrug effects
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIrinotecan _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aOxaliplatin _xadministration & dosage
650	0	4	_aStomach Neoplasms _xdrug therapy
650	0	4	_aYoung Adult
700	1		_aMulder, Karen
700	1		_aBrezden-Masley, Christine
700	1		_aVickers, Michael
700	1		_aMonzon, Jose
700	1		_aKennecke, Hagen
700	1		_aGoel, Rakesh
700	1		_aVos, Larissa
700	1		_aGhosh, Sunita
700	1		_aMarginean, Horia
700	1		_aFields, Anthony
700	1		_aMaroun, Jean
700	1		_aSpratlin, Jennifer
773	0		_tInvestigational new drugs _gvol. 36 _gno. 4 _gp. 674-682
856	4	0	_uhttps://doi.org/10.1007/s10637-018-0599-4 _zAvailable from publisher's website
999			_c28356534 _d28356534